Sana Biotechnology (NASDAQ:SANA) Shares Down 3.4%

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price traded down 3.4% on Wednesday . The company traded as low as $5.16 and last traded at $5.17. 467,107 shares were traded during mid-day trading, a decline of 82% from the average session volume of 2,635,602 shares. The stock had previously closed at $5.35.

Analysts Set New Price Targets

SANA has been the subject of several recent research reports. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Sana Biotechnology in a report on Thursday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.75.

Sana Biotechnology Stock Down 4.4 %

The stock has a 50-day moving average of $7.44 and a 200 day moving average of $7.40. The company has a market capitalization of $1.11 billion, a PE ratio of -3.28 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Equities analysts forecast that Sana Biotechnology, Inc. will post -1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SANA. Capital World Investors raised its holdings in Sana Biotechnology by 255.8% during the 1st quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock valued at $54,490,000 after acquiring an additional 3,917,728 shares during the period. Vanguard Group Inc. lifted its holdings in Sana Biotechnology by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after purchasing an additional 2,358,089 shares in the last quarter. PFM Health Sciences LP boosted its stake in Sana Biotechnology by 51.4% in the 4th quarter. PFM Health Sciences LP now owns 1,883,337 shares of the company’s stock worth $7,684,000 after purchasing an additional 639,198 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Sana Biotechnology during the third quarter valued at about $2,091,000. Finally, Baillie Gifford & Co. lifted its holdings in shares of Sana Biotechnology by 5.0% in the first quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock worth $106,563,000 after buying an additional 506,262 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.